Clinical Applications of Nanobodies
| Enhanced Diagnostic | Nuclear Medicine | Drug discovery & ADC drug | Improved CAR-T |
Highlights of our servicess
Recombinant VHH Antibodies
VHH (Nanobody), also known as Camelid single domain antibody (sdAb), is the recombinant variable domain derived from camelid heavy-chain-only antibody. The small size (15 kDa) and high stability of VHH antibody make it a promising tool for disease diagnosis and treatment. For example, thanks to their small size (15 kDa), VHH can be transported more easily through certain physiological barriers. Additionally, VHH antibody expresses well in many host systems, making it cost-effective for large-scale manufacturing
VHH (Nanobody) vs. Conventional Mab
| Feature | Antibody | VHH (Nanobody) |
| Immunogenicity | High | Low |
| Molecular weight | 150 kDa | 12–15 kDa |
| Half-life | Long | Short |
| Tissue penetration | Low | Strong, it can cross the blood–brain barrier |
| CDR3 length | 10 amino acid residues on average | 16-24 amino acid residues |
| Recognition site | Harder to identify hidden sites | Easier to identify hidden sites |
| Stability | Prone to degradation and changes in temperature and pH | High stability. Tolerant to temperature, pressure, and pH changes |
| Antibody expression | Mammalian expression | Mammalian or microbial expression |
| Production cost | Highly | Low |
| Engineering modification | “Y”-shaped structure, not easy to modify | Simple structure that can be easily modified |
Unique Advantages of VHH (Nanobody)
Service type
Nanobody Development and Production Platform
| Feature | A. Naïve Library | B. Immune Library |
| Required antigen | 0.8-1mg | 3-5mg |
| Lead Time | 8-10 weeks | 4-6 months |
| Half-life | Poor | Better |
| Specificity | Poor | Excellent |
| Deliverables | •ELISA data. •1-3 different VH •sequences. •1 purified VHH, approximately 0.5mg per VHH. |
•cDNA 150ug. •ELISA data. •1-5different VHH sequences. •1 purified VHH, approximately 0.5mg per VHH. |
